Share on StockTwits

Relypsa (NASDAQ:RLYP) Director Klaus R. Dr Veitinger sold 4,167 shares of the stock on the open market in a transaction dated Thursday, July 10th. The shares were sold at an average price of $23.12, for a total value of $96,341.04. Following the completion of the transaction, the director now directly owns 2,712 shares of the company’s stock, valued at approximately $62,701. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

RLYP has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of Relypsa from $56.00 to $57.00 in a research note on Tuesday, May 13th. They now have an “outperform” rating on the stock. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Relypsa in a research note on Thursday, May 8th. They now have a $45.00 price target on the stock, down previously from $49.00. Eight investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $48.17.

Shares of Relypsa (NASDAQ:RLYP) traded up 0.86% on Friday, hitting $23.50. The stock had a trading volume of 133,012 shares. Relypsa has a 1-year low of $11.55 and a 1-year high of $52.74. The stock has a 50-day moving average of $23.9 and a 200-day moving average of $29.31. The company’s market cap is $795.4 million. Relypsa also was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,491,734 shares, a growth of 65.6% from the June 13th total of 900,722 shares. Based on an average daily trading volume, of 457,574 shares, the days-to-cover ratio is presently 3.3 days. Approximately 6.3% of the company’s shares are sold short.

Relypsa (NASDAQ:RLYP) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.02. On average, analysts predict that Relypsa will post $-2.50 earnings per share for the current fiscal year.

Relypsa, Inc is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.